VIR_logo_large.jpg
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)
22 févr. 2023 08h30 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the UK’s National Institute for Health and Care Excellence (NICE) provided positive final...
VIR_logo_large.jpg
Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details
18 mai 2022 16h03 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, May 18, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2022 Annual General Meeting of Stockholders on Friday, May 20,...
VIR_logo_large.jpg
Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19
17 déc. 2021 08h16 HE | Vir Biotechnology, Inc.
LONDON and SAN FRANCISCO, Dec. 17, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Commission (EC) has...
VIR_logo_large.jpg
Vir Biotechnology Announces First Marketing Authorization for its First Commercial Product, Sotrovimab, Granted in Australia
23 août 2021 08h30 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the first marketing authorization, granted in Australia, for its first commercial product,...